Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia

European Archives of Psychiatry and Clinical Neuroscience

Volumn 257, Issue 7, 2007, Pages 402-412

  Riedel, Michael ^a   Müller, Norbert ^a   Spellmann, Ilja ^a   Engel, Rolf R ^a   Musil, Richard ^a   Valdevit, Rosamaria ^a   Dehning, Sandra ^a   Douhet, Anette ^a   Cerovecki, Anja ^a   Strassnig, Martin ^b   Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Atypical antipsychotics; Cognitive improvement; Olanzapine; Quetiapine; Schizophrenia

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SCREENING; FEMALE; HUMAN; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NONPARAMETRIC TEST; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COGNITION DISORDERS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; STATISTICS, NONPARAMETRIC;

EID: 34249905372     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-007-0748-9     Document Type: Article

References (59)

1. Arnsten AF (2004) Adrenergic targets for the treatment of cognitive deficits in schizophrenia. Psychopharmacology (Berl) 174:25-31
2. Arnsten AF, Cai JX (1993) Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine. Neurobiol Aging 14:597-603
3. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI (1997) Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr Res 25:1-10
4. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, Lieberman JA (2002) Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028
5. Birnbaum S, Gobeske KT, Auerbach J, Taylor JR, Arnsten AF (1999) A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry 46:1266-1274
6. Bleuler E (1950) In: Zinkin J (ed) Dementia praecox for the group of schizophrenias. International University Press, New York
7. Bourson A, Boess FG, Bos M, Sleight AJ (1998) Involvement of 5-HT6 receptors in nigro-striatal function in rodents. Br J Pharmacol 125:1562-1566
8. Cuesta MJ, Peralta V, Zarzuela A (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48:17-28
9. Friedman JI, Temporini H, Davis KL (1999) Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry 45:1-16
10. Ghoneim MM, Mewaldt SP (1977) Studies on human memory: the interactions of diazepam, scopolamine, and physostigmine. Psychopharmacology (Berl) 52:1-6
11. Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997) Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 54:159-165
12. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48
13. Good KP, Kiss I, Buiteman C, Woodley H, Rui Q, Whitehorn D, Kopala L (2002) Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br J Psychiatry Suppl 43:45-49
14. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, Liberman RP, Mintz J (2002) The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 51:972-978
15. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301-307
16. Gutbrod K, Cohen R, Mager B, Meier E (1989) Coding and recall of categorized material in aphasics. J Clin Exp Neuropsychol 11:821-841
17. Hawkins KA (1999) Memory deficits in patients with schizophrenia: preliminary data from the Wechsler memory scalethird edition support earlier findings. J Psychiatry Neurosci 24:341-347
18. Hawkins KA, Hoffman RE, Quinlan DM, Rakfeldt J, Docherty NM, Sledge WH (1997) Cognition, negative symptoms, and diagnosis: a comparison of schizophrenic, bipolar, and control samples. J Neuropsychiatry Clin Neurosci 9:81-89
19. Heaton R, Paulsen JS, McAdams LA, Kuck J, Zisook S, Braff D, Harris J, Jeste DV (1994) Neuropsychological deficits in schizophrenics. Relationship to age, chronicity, and dementia. Arch Gen Psychiatry 51:469-476
20. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV (2001) Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 58:24-32
21. Hertel P, Fagerquist MV, Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 286:105-107
22. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE (1999) Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry 156:1336-1341
23. Hughes C, Kumari V, Soni W, Das M, Binneman B, Drozd S, O'Neil S, Mathew V, Sharma T (2003) Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophr Res 59:137-146
24. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002) Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771
25. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369
26. Keefe RS, Roitman SE, Harvey PD, Blum CS, DuPre RL, Prieto DM, Davidson M, Davis KL (1995) A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia. Schizophr Res 17:25-33
27. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA (2004) Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double- blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161:985-995
28. Keefe RS, Silva SG, Perkins DO, Lieberman JA (1999) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25:201-222
29. Kraepelin E (1919) Dementia Praecox and Paraphrenia. (Translated by Barclay RM, Robertson GM) Lifingstone, Edinborugh
30. Lehrl S (1977) Mehrfachwahl-Wortschatz-Intelligenztest. Manual zum MWT-B. Straube, Erlangen
31. Lewis R (2004) Should cognitive deficit be a diagnostic criterion for schizophrenia? J Psychiatry Neurosci 29:102-113
32. Mckeage K, Plosker GL (2004) Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18:933-956
33. Meltzer HY (2004) Cognitive factors in schizophrenia: causes, impact, and treatment. CNS Spectr 9:15-24
34. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172
35. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
36. Mewaldt SP, Ghoneim MM (1979) The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 10:205-210
37. Mishara AL, Goldberg TE (2004) A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55:1013-1022
38. Moeller HJ (2003) Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatr 27:1101-1111
39. Peuskens J, Demily C, Thibaut F (2005) Treatment of cognitive dysfunction in schizophrenia. Clin Ther 27(Suppl A):25-37
40. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, Breier A, Tollefson GD (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 57:249-258
41. Purdon SE, Malla A, Labelle A, Lit W (2001) Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26:137-149
42. Reitan RM (1958) Validity of the trailmaking test as an indication of organic brain damage. Percept Mot Skills 8:271-276
43. Rey A (1958) Ĺexamen clinique en psychologie. Presse Universitaire de France, Paris
44. Riedel M, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Muller N, Moller HJ (2007) Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci, in press
45. Riemer C, Borroni E, Levet-Trafit B, Martin JR, Poli S, Porter RH, Bos M (2003) Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4- sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 46:1273-1276
46. Sacchetti E, Valsecchi P, Regini C, Galluzzo A, Cacciani P, Agrimi E, Mencacci C (2004) Comparison of quetiapine (Seroquel), olanzapine and risperidone in a randomised study in patients with schizophrenia
47. Shayegan DK, Stahl SM (2004) Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 9:6-14
48. Smith RC, Infante M, Singh A, Khandat A (2001) The effects of olanzapine on neurocognitive functioning in medicationrefractory schizophrenia. Int J Neuropsychopharmacol 4:239-250
49. Spreen O, Benton AL (1965) Comparative studies of some psychological tests for cerebral damage. J Nerv Ment Dis 140:323-333
50. Tune LE, Strauss ME, Lew MF, Breitlinger E, Coyle JT (1982) Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 139:1460-1462
51. Tyson PJ, Roberts KH, Mortimer AM (2004) Are the cognitive effects of atypical antipsychotics influenced by their affinity to 5HT-2A receptors? Int J Neurosci 114:593-611
52. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC (2000) Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 188:518-524
53. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R, Miller AL (2002) Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53:239-248
54. Velligan DI, Prihoda TJ, Sui D, Ritch JL, Maples N, Miller AL (2003) The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J Clin Psychiatry 64:524-531
55. Vitiello B, Martin A, Hill J, Mack C, Molchan S, Martinez R, Murphy DL, Sunderland T (1997) Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans. Neuropsychopharmacology 16:15-24
56. Voruganti LN, Heslegrave RJ, Awad AG (1997) Neurocognitive correlates of positive and negative syndromes in schizophrenia. Can J Psychiatry 42:1066-1071
57. Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn KU (2005) Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 30:381-390
58. Walker E, Harvey P (1986) Positive and negative symptoms in schizophrenia: attentional performance correlates. Psychopathology 19:294-302
59. Wiebel B, Happe A, Peikara F (1995) Das neuropsychologische Diagnostikprogramm TESTBAT. PSYMED, Dulmen